Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
globalreutersNovember 21, 20241 Mins read 
Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally. Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals’ Revuforj, which won FDA approval last week.
The post Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin appeared first on MedCity News.
Related Articles
How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...
Everything You Need to Know About Hip Replacement Surgery in India
Hip replacement surgery is one of the most common and successful medical...
Speculation on RFK Jr. as HHS Secretary
From Tyler Cowen at Marginal Revolution: One of the problems with an...
Crothall’s Innovation Summit Unveils Cutting-Edge Cleaning Solutions for UCI Health
A one-day conference featuring exhibits by Crothall Healthcare’s leading product suppliers is...
Leave a comment